In plain English
The same peptide (a short chain of amino acids) can be sold in two very different ways. What differs is how the product is checked and controlled.
An approved medicine has been tested in people, reviewed by a regulator (a government body such as the TGA) and entered on the ARTG, the official list of medicines that can be supplied in Australia [1, 2]. It is made in a licensed factory that follows GMP (good manufacturing practice, a strict system of quality rules) [3].
A research peptide has none of this. It is a chemical for laboratory work. Its quality rests on its specification and on testing of each batch, and real-world testing has found products far from their labels [4]. Even when the sequence is the same, it is not the same product as a medicine and has not been checked by a regulator.
The short version
- A research peptide is a different product from a medicine, even when the molecule is the same.
- Approved medicines are assessed by a regulator and listed on the ARTG.
- Research peptides are not assessed and are not for human or animal use.
- A “research use only” label does not make supply lawful [14].
At a glance
| Approved peptide medicine | Research peptide | |
|---|---|---|
| Regulator assessment | Evaluated by the TGA for quality, safety and efficacy before registration [1] | Not assessed by the TGA [5] |
| ARTG entry | Registered on the ARTG with an AUST R number [1] | Not entered on the ARTG [5] |
| Manufacturing standard | Made under a manufacturing licence or GMP clearance, to the PIC/S Guide to GMP [3] | No regulator-verified GMP status; quality depends on the supplier’s own controls and batch testing |
| Evidence base | Clinical trial data reviewed by the regulator [1, 6] | Usually published cell and animal studies; human data are often limited or absent |
| Product information | Approved Product Information and Consumer Medicine Information [2] | A specification and, ideally, a batch-specific Certificate of Analysis |
| Post-market monitoring | Ongoing safety monitoring and sponsor obligations [1] | None by a medicines regulator |
| Access | By prescription, through a pharmacist [1, 7] | Not for human or animal use |
What makes a medicine “approved” in Australia?
A medicine is approved when the TGA has evaluated it and entered it on the ARTG. The ARTG is the public register of medicines, medical devices and biologicals that can be supplied in Australia [2].
For prescription medicines, the TGA evaluates safety, quality and efficacy before registration. A registered prescription medicine carries an AUST R number on its label [1]. The TGA lists several pathways for registration [1]:
- the standard pathway
- priority review
- provisional determination
- the Comparable Overseas Regulators (COR) pathway.
Not every medicine accepted for evaluation is approved. After approval, the sponsor must keep meeting regulatory requirements, and the TGA continues to monitor the medicine’s safety [1].
Other regulators run comparable systems. In the United States, for example, the FDA reviews the sponsor’s laboratory, animal and clinical data and approves a drug only when it judges that the evidence outweighs the known and potential risks for the intended population. The FDA generally expects data from two well-designed clinical trials [6].
What is GMP and why does it matter?
Good Manufacturing Practice (GMP) is a set of principles and procedures that, when followed by medicine manufacturers, helps make sure products consistently have the required quality [3]. In Australia, medicines must be manufactured under the PIC/S Guide to GMP, which the TGA applies as its manufacturing principles. Australian manufacturers need a TGA manufacturing licence, and overseas manufacturers need GMP clearance or certification [3].
For active pharmaceutical ingredients (APIs), the international reference is ICH Q7, the GMP guide for APIs [8]. GMP covers far more than the final purity figure. It includes:
- a quality management system with an independent quality unit
- qualified personnel and controlled premises and equipment
- validated processes and analytical methods
- full documentation and batch records
- controlled release of each batch [8].
A research peptide can be very pure and still not be GMP material. “GMP” describes the whole manufacturing system, not a single test result. Under our editorial standards, we only use terms like “GMP” when we hold the document proving it for that batch.
Quality standards: what a research peptide’s quality rests on
Without regulatory oversight, a research peptide’s quality rests on three things: its specification, the analytical testing of each batch, and whether that testing can be traced to the vial.
Synthetic peptides can carry several kinds of impurity. These include deletion and insertion sequences, incompletely deprotected chains, oxidation products, aggregates and leftover counter-ions such as trifluoroacetate. A review of peptide impurities also reported contamination of peptide products with unrelated peptides, which the authors linked to a lack of appropriate GMP [9].
Real-world testing shows how far unregulated products can drift from their labels. In a 2024 study, semaglutide vials bought from online sellers without a prescription were labelled 99% pure. Measured purity was 7.7–14.4%, peptide content exceeded the label by 28.6–38.7%, and endotoxin was detected in every sample [4].
For research material, the minimum is a batch-specific Certificate of Analysis, with identity confirmed by mass spectrometry and purity by HPLC. See How to Read a Peptide Certificate of Analysis and How to Evaluate a Research Peptide Supplier.
Examples of approved peptide medicines
Peptide medicines are a well-established drug class. A 2021 review counted more than 80 peptide drugs on the market worldwide [10]. Examples include:
| Example | Note |
|---|---|
| Insulin products | Approved by the TGA and included on the ARTG [14] |
| Semaglutide and liraglutide | Approved peptide drugs modified with a fatty-acid chain [11] |
| Vasopressin | Listed by Sport Integrity Australia as a registered peptide medicine [12] |
| Somatropin (growth hormone) | Listed by Sport Integrity Australia as a registered medicine; strictly a protein rather than a short peptide [12] |
These are regulated pharmaceutical products. Research-grade material with the same or a similar sequence is not that product, has not been assessed by a regulator, and is not equivalent to it.
Same sequence, different product
Two vials that contain the “same peptide” are not interchangeable. An approved medicine is defined by much more than its sequence:
- a validated manufacturing process at a licensed or GMP-cleared site [3, 8]
- an independent quality unit that reviews batch records before release [8]
- approved specifications, stability monitoring and expiry or retest dating for the active ingredient [8]
- a registered product that has been evaluated as a whole, with clinical evidence reviewed by the regulator [1, 6].
Research material shares none of these by default.
What this means in Australia
- ARTG. A medicine is approved for supply in Australia when the TGA has evaluated it and entered it on the ARTG [1, 2]. Unapproved peptide products are goods that are not on the ARTG and have not been assessed by the TGA for safety, quality or effectiveness [14].
- Poisons Standard. Scheduling is separate from ARTG status and is set compound by compound. Schedule 4 means prescription-only [7]. Some research peptides are named in the current Poisons Standard (October 2026). For example, BPC-157 and TB-500 are Schedule 4 and Appendix D, clause 5, which means possessing them without authority is illegal [15]. Others are not named. Not being named does not mean a substance is unregulated; the TGA regards unapproved peptide products as therapeutic goods subject to import, supply and advertising controls [14].
- Lawful access pathways. Australia has defined pathways for accessing goods that are not on the ARTG, including the Special Access Scheme, the Authorised Prescriber Scheme and the clinical trial schemes [5]. Each has conditions; for example, the clinical trial schemes govern experimental use of unapproved goods in humans [13].
- “Research use only” is not a pathway. The TGA has stated that such a disclaimer does not make supply lawful. It does not change a product’s regulatory status, permit importation, or remove advertising or supply obligations [14]. The Poisons Standard also notes that its labelling exemption for poisons sold solely for laboratory use does not extend to controls on supply [15].
- Advertising and labelling. The TGA has said that advertising unapproved therapeutic goods to Australian consumers is generally unlawful, including on websites. It also counts applying a label to a blank vial as a step in manufacture [16].
For the full legal framework, see Are Peptides Legal in Australia?.
This is general information, not legal advice. Laws change; check the current Poisons Standard and TGA guidance.
Frequently asked questions
Are research peptides the same as prescription peptides?
No. A prescription peptide medicine has been assessed by a regulator, is made under GMP and is on the ARTG. A research peptide has not been assessed and is not equivalent, even if the sequence matches [1, 3, 5].
What does “not on the ARTG” mean?
It means the TGA has not assessed the product for safety, quality or effectiveness, and it cannot generally be supplied as a therapeutic good in Australia outside a lawful access pathway [5].
Does high purity make a research peptide equivalent to a medicine?
No. Purity is one test result. An approved medicine also requires a licensed GMP manufacturing system, approved specifications, stability monitoring and regulator-reviewed clinical evidence for that product [1, 3, 8].
What is the difference between GMP and a Certificate of Analysis?
GMP is a whole manufacturing and quality system that is inspected by regulators. A Certificate of Analysis reports test results for one batch. A COA can be valuable, but it does not show GMP compliance [3, 8].
Can a “research use only” label make supply lawful?
The TGA states that it cannot. Such disclaimers do not change a product’s regulatory status or permit importation [14].
References
- Therapeutic Goods Administration. Prescription medicines. tga.gov.au/products/medicines/prescription-medicines. Accessed 11 October 2026.
- Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG). tga.gov.au/resources/artg. Accessed 11 October 2026.
- Therapeutic Goods Administration. Manufacturing medicines. tga.gov.au. Accessed 11 October 2026.
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res. 2024;26:e65440. doi:10.2196/65440. PMID: 39509151
- Therapeutic Goods Administration. Unapproved therapeutic goods. tga.gov.au/products/unapproved-therapeutic-goods. Accessed 11 October 2026.
- US Food and Drug Administration. Development & Approval Process | Drugs. fda.gov/drugs/development-approval-process-drugs. Accessed 11 October 2026.
- Australian Government. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Reader’s guide: Classification (Schedule 4). Federal Register of Legislation F2026L01327. legislation.gov.au/F2026L01327/latest/text. Accessed 11 October 2026.
- International Council for Harmonisation. ICH Q7: Good manufacturing practice guide for active pharmaceutical ingredients. database.ich.org. Accessed 11 October 2026.
- D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012. PMID: 25044089
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309–325. doi:10.1038/s41573-020-00135-8. PMID: 33536635
- Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48. doi:10.1038/s41392-022-00904-4. PMID: 35165272
- Sport Integrity Australia. Peptides explained. sportintegrity.gov.au. Accessed 11 October 2026.
- Therapeutic Goods Administration. Clinical trials. tga.gov.au/products/unapproved-therapeutic-goods/clinical-trials. Accessed 11 October 2026.
- Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 April 2026. tga.gov.au. Accessed 11 October 2026.
- Australian Government. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, including the Reader’s guide: Introduction and the Schedule 4 and Appendix D entries. Federal Register of Legislation F2026L01327. legislation.gov.au/F2026L01327/latest/text. Accessed 11 October 2026.
- Therapeutic Goods Administration. Unapproved peptide product promoters and suppliers are put on notice. Media release, 20 July 2026. tga.gov.au. Accessed 11 October 2026.
Important information and disclaimer
General information only. This article is published for general educational and informational purposes. It summarises published scientific literature and public regulatory information as at the “last reviewed” date shown above. It is not medical, health, pharmaceutical, veterinary or legal advice, and it must not be relied on as a substitute for advice from a qualified professional about your circumstances.
Not for human or animal use. Nothing in this article recommends, endorses or describes the use of any substance in humans or animals. Findings from cell, animal or early human studies cannot be assumed to apply to people. The compounds discussed have not been evaluated by the Therapeutic Goods Administration (TGA) for safety, quality or efficacy unless the article expressly states otherwise. Any research materials offered by Iconic Peptides are supplied solely for in vitro and laboratory research.
No therapeutic claims. Iconic Peptides makes no claim that any product treats, cures, prevents, alleviates or diagnoses any disease, condition or symptom. References to published studies, clinical trials or medicines approved by regulators are factual descriptions of the scientific and regulatory record. They are not representations about any product we supply.
Regulatory status. Many peptides are scheduled substances under the Poisons Standard. Some are prescription-only (Schedule 4), and some may not be possessed without authority (Appendix D). The TGA has stated that a “research use only” label does not make supply lawful, change a product’s regulatory status, or remove advertising or supply obligations. State and territory laws may also apply. You are responsible for knowing and complying with all laws that apply to you. Regulatory information in this article may change after the review date.
Accuracy and third-party sources. We take care to cite and verify every source, but we do not warrant that this article is complete, current or error-free. Citing a study or organisation does not mean that its authors or that organisation endorse Iconic Peptides.
Limitation of liability. To the maximum extent permitted by law, Iconic Peptides, its owners, employees and contributors exclude all liability for any loss, damage, injury or expense, whether direct, indirect or consequential, arising from use of or reliance on this article or any misuse of any product. Nothing in this disclaimer excludes, restricts or modifies any right or remedy under the Australian Consumer Law that cannot lawfully be excluded.
Age restriction. This website is intended for adults aged 18 and over.
